Arbutus Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Arbutus Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Arbutus Biopharma Analyst Ratings
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Arbutus Biopharma Analyst Ratings
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
Arbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospects
Promising Phase IIa Trial Results Bolster Buy Rating for Arbutus Biopharma: An Analysis of VTP-300's Potential and Future Trials
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arbutus Biopharma (ABUS) and Bluebird Bio (BLUE)
Promising Developments in HBV Treatment: A Comprehensive Analysis of Arbutus Biopharma's AB-729-202 Phase 2a Study and Buy Rating Justification
Arbutus Biopharma Earns Buy Rating: Strong Financial Position, Workforce Changes, and Promising Hepatitis B Treatment Developments
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating